Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+HibTM) in Healthy Vietnamese Toddlers

NCT01577732 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01577732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01577732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+HibTM) in Healthy Vietnamese Toddlers
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
December 8, 2012
Completion date
April 9, 2013
Enrollment
321 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, diphtheria-tetanus-apertussis-poliomyelitis-haemophilus influenzae type b vaccines, haemophilus influenzae type b, poliomyelitis, tetanus